Literature DB >> 16552035

Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia.

Michael A Pammit1, Erin K Raulie, Crystal M Lauriano, Karl E Klose, Bernard P Arulanandam.   

Abstract

Francisella tularensis is an intracellular gram-negative bacterium that is the causative agent of tularemia and a potential bioweapon. We have characterized the efficacy of a defined F. novicida mutant (DeltaiglC) as a live attenuated vaccine against subsequent intranasal challenge with the wild-type organism. Animals primed with the F. novicida DeltaiglC (KKF24) mutant induced robust splenic gamma interferon (IFN-gamma) and interleukin-12 (IL-12) recall responses with negligible IL-4 production as well as the production of antigen-specific serum immunoglobulin G1 (IgG1) and IgG2a antibodies. BALB/c mice vaccinated intranasally (i.n.) with KKF24 and subsequently challenged with wild-type F. novicida (100 and 1,000 50% lethal doses) were highly protected (83% and 50% survival, respectively) from the lethal challenges. The protection conferred by KKF24 vaccination was shown to be highly dependent on endogenous IFN-gamma production and also was mediated by antibodies that could be adoptively transferred to naive B-cell-deficient mice by inoculation of immune sera. Collectively, the results demonstrate that i.n. vaccination with KKF24 induces a vigorous Th1-type cytokine and antibody response that is protective against subsequent i.n. challenge with the wild-type strain. This is the first report of a defined live attenuated strain providing protection against the inhalation of F. novicida.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552035      PMCID: PMC1418901          DOI: 10.1128/IAI.74.4.2063-2071.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection.

Authors:  Michael A Pammit; Varija N Budhavarapu; Erin K Raulie; Karl E Klose; Judy M Teale; Bernard P Arulanandam
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Modulation of biogenesis of the Francisella tularensis subsp. novicida-containing phagosome in quiescent human macrophages and its maturation into a phagolysosome upon activation by IFN-gamma.

Authors:  Marina Santic; Maelle Molmeret; Yousef Abu Kwaik
Journal:  Cell Microbiol       Date:  2005-07       Impact factor: 3.715

3.  Aerogenic immunization of man with live Tularemia vaccine.

Authors:  R B Hornick; H T Eigelsbach
Journal:  Bacteriol Rev       Date:  1966-09

4.  Allelic exchange in Francisella tularensis using PCR products.

Authors:  Crystal M Lauriano; Jeffrey R Barker; Francis E Nano; Bernard P Arulanandam; Karl E Klose
Journal:  FEMS Microbiol Lett       Date:  2003-12-12       Impact factor: 2.742

5.  Factors affecting the escape of Francisella tularensis from the phagolysosome.

Authors:  Helena Lindgren; Igor Golovliov; Vladimir Baranov; Robert K Ernst; Max Telepnev; Anders Sjöstedt
Journal:  J Med Microbiol       Date:  2004-10       Impact factor: 2.472

6.  Survival, replication, and antibody susceptibility of Ehrlichia chaffeensis outside of host cells.

Authors:  Julia Shu-Yi Li; Gary M Winslow
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival.

Authors:  Crystal M Lauriano; Jeffrey R Barker; Sang-Sun Yoon; Francis E Nano; Bernard P Arulanandam; Daniel J Hassett; Karl E Klose
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

8.  Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages.

Authors:  Daniel L Clemens; Bai-Yu Lee; Marcus A Horwitz
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

9.  Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica.

Authors:  Stephan Stenmark; Helena Lindgren; Arne Tärnvik; Anders Sjöstedt
Journal:  Microb Pathog       Date:  2003-08       Impact factor: 3.738

10.  Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice.

Authors:  Ashlesh K Murthy; Jyotika Sharma; Jacqueline J Coalson; Guangming Zhong; Bernard P Arulanandam
Journal:  Cell Immunol       Date:  2004-07       Impact factor: 4.868

View more
  33 in total

1.  The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge.

Authors:  J-J Yu; E K Raulie; A K Murthy; M N Guentzel; K E Klose; B P Arulanandam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-18       Impact factor: 3.267

2.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

3.  T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria.

Authors:  Carmen M Collazo; Anda I Meierovics; Roberto De Pascalis; Terry H Wu; C Rick Lyons; Karen L Elkins
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

4.  Genome-wide screen in Francisella novicida for genes required for pulmonary and systemic infection in mice.

Authors:  Petra S Kraemer; Allison Mitchell; Mark R Pelletier; Larry A Gallagher; Mike Wasnick; Laurence Rohmer; Mitchell J Brittnacher; Colin Manoil; Shawn J Skerett; Nina R Salama
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

5.  Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.

Authors:  Jieh-Juen Yu; Tatareddy Goluguri; M Neal Guentzel; James P Chambers; Ashlesh K Murthy; Karl E Klose; Thomas G Forsthuber; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-12-16

Review 6.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

7.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

8.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

9.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

10.  TLR-dependent control of Francisella tularensis infection and host inflammatory responses.

Authors:  Allison L Abplanalp; Ian R Morris; Bijaya K Parida; Judy M Teale; Michael T Berton
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.